These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 15293769)

  • 1. Pharmacoeconomic evaluation of antidepressant therapies.
    Sarnes MW; Frankum LE
    Manag Care; 2004 Jun; 13(6 Suppl Depression):34-41. PubMed ID: 15293769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic evaluation of antidepressive agents: a systematic critique of experimental and observational studies.
    Barbui C; Percudani M; Hotopf M
    J Clin Psychopharmacol; 2003 Apr; 23(2):145-54. PubMed ID: 12640216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The management of depression: the implications for managed care--roundtable discussion: Part 2.
    Arikian S; Casciano J; Kang-Cipolla L; Vodoor M; Grubin M; Clark D; Waugh W; Kelsey J; Osborn LW
    Manag Care Interface; 2000; Suppl B():19-25, 32. PubMed ID: 11183021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness comparisons using "real world" randomized trials: the case of new antidepressant drugs.
    Simon G; Wagner E; Vonkorff M
    J Clin Epidemiol; 1995 Mar; 48(3):363-73. PubMed ID: 7897458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): a comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs.
    Doyle JJ; Casciano J; Arikian S; Tarride JE; Gonzalez MA; Casciano R
    Value Health; 2001; 4(1):16-31. PubMed ID: 11704969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effective treatment of depression with selective serotonin reuptake inhibitors.
    Panzarino PJ; Nash DB
    Am J Manag Care; 2001 Feb; 7(2):173-84. PubMed ID: 11216334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A critical review of selected pharmacoeconomic analyses of antidepressant therapy.
    Conner TM; Crismon ML; Still DJ
    Ann Pharmacother; 1999 Mar; 33(3):364-72. PubMed ID: 10200863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using pharmacoeconomic data to compare antidepressant therapies.
    Manag Care; 2001 Aug; 10(8 Suppl):14-5; discussion 18-22. PubMed ID: 11729433
    [No Abstract]   [Full Text] [Related]  

  • 9. C-QUALITY: cost and quality-of-life pharmacoeconomic analysis of antidepressants in major depressive disorder in Italy.
    Mencacci C; Aguglia E; Biggio G; Cappellari L; Di Sciascio G; Fagiolini A; Maina G; Tortorella A; Katz P; Ripellino C
    Adv Ther; 2013 Jul; 30(7):697-712. PubMed ID: 23929174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic outcomes with antidepressant pharmacotherapy: a retrospective intent-to-treat analysis.
    Sclar DA; Skaer TL; Robison LM; Galin RS; Legg RF; Nemec NL
    J Clin Psychiatry; 1998; 59 Suppl 2():13-7. PubMed ID: 9559755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of formulary restrictions on the cost-effectiveness of antidepressant treatment.
    Sheehan DV; Wright-Etter PJ
    Manag Care Q; 2002; 10(3):21-31. PubMed ID: 12476662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pharmaco-economic aspects of antidepressants and antipsychotic drugs].
    Laux G
    Psychiatr Prax; 2003 May; 30 Suppl 2():S90-3. PubMed ID: 14509049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost-effectiveness of sertraline in the treatment of depression.
    Olvey EL; Skrepnek GH
    Expert Opin Pharmacother; 2008 Oct; 9(14):2497-508. PubMed ID: 18778187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antidepressant utilization in managed care: an evaluation of SSRI use in two HMO settings.
    Navarro R; Valler WE; Spangler M
    Med Interface; 1995 Aug; 8(8):114-9, 123. PubMed ID: 10144769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-benefit & cost-effectiveness analysis of the rapid onset of selective serotonin reuptake inhibitors by augmentation.
    Tome MB; Isaac MT
    Int J Psychiatry Med; 1997; 27(4):377-90. PubMed ID: 9565733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trends in the consumption of antidepressant drugs in Lithuania in 2002-2004.
    Kadusevicius E; Mikucionyte L; Maciulaitis R; Milvidaite I; Sveikata A
    Medicina (Kaunas); 2006; 42(12):1020-9. PubMed ID: 17211111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Newer antidepressants for the treatment of depression in adults.
    Hatcher S; Arroll B
    BMJ; 2012 Jan; 344():d8300. PubMed ID: 22262785
    [No Abstract]   [Full Text] [Related]  

  • 18. Cost-utility comparison of escitalopram and sertraline in the treatment of major depressive disorder.
    Armstrong EP; Skrepnek GH; Haim Erder M
    Curr Med Res Opin; 2007 Feb; 23(2):251-8. PubMed ID: 17288678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antidepressant adherence and medical resource use among managed care patients with anxiety disorders.
    Stein MB; Cantrell CR; Sokol MC; Eaddy MT; Shah MB
    Psychiatr Serv; 2006 May; 57(5):673-80. PubMed ID: 16675762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combining mirtazapine with SSRIs or SNRIs for treatment-resistant depression: the MIR RCT.
    Kessler D; Burns A; Tallon D; Lewis G; MacNeill S; Round J; Hollingworth W; Chew-Graham C; Anderson I; Campbell J; Dickens C; Macleod U; Gilbody S; Davies S; Peters TJ; Wiles N
    Health Technol Assess; 2018 Nov; 22(63):1-136. PubMed ID: 30468145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.